glp-1 in heart failure The cardiovascular effects of receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Frontiers | The potential of
Description
& Min, T
This contribution requires GLP-1R signaling in the brain
Microdosing The Approach There is no formal definition of what constitutes a microdose for GLP-1 medications
Mitochondrial dysfunction is not uniformly distributed across the brain
The BMJ
What it doesnt do is optimize that concept or address the full range of metabolic challenges that make weight loss difficult to achieve and even harder to maintain
